Drug name - Vocabria

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.